Several COVID-19 vaccines, including Pfizer’s version, are about 95 percent effective in preventing disease. But there’s less known about whether vaccinated individuals can still transmit the SARS-CoV ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly fewer reactogenicity events than Pfizer ... Novavax’s COVID-19 shot.

The COVID pandemic has infected more than ... I had an opportunity to sit down with Dr. William Gruber-- he's Pfizer's senior vice president of vaccine clinical research and development-- to ...

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

Scientists reveal what vaccines are really capable of As new COVID-19 variants continue to emerge, widespread concerns have ...

The representations made by Pfizer about its COVID-19 vaccine have been accurate and science-based,” the company said. Kobach ...

And both groups do have a reason to celebrate as the two mRNA vaccines available in the US have proved to be highly effective against severe COVID-19. #TeamModerna when ... infections have been ...

Updated Dec. 8 at 1:30 p.m. Pfizer enrolled ... whether they received the vaccine or the placebo. The study began in late July, and participants were exposed to the coronavirus as they went ...

Rob Roos, a Dutch member of the European Parliament, shared a video that cast doubt on the Pfizer COVID vaccine ... was not a study endpoint and the trials were centered on the vaccine's efficacy.

It's not the first time Pfizer and BioNTech have been accused of patent infringement with Comirnaty, as another mRNA COVID-19 vaccine developer – CureVac – filed a suit in Germany last month ...

1 strain resulted in fewer and less severe reactogenicity symptoms, when compared with the Pfizer-BioNTech mRNA 2024-2025 vaccine. This real-world study conducted between September and December ...